Armoured GPC3 CAR T Cells Show Promise Against Liver Cancer, but Hurdles Remain

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of certain blood cancers, but solid tumours have remained stubbornly resistant to the approach. Now, a new clinical product targeting glypican 3 (GPC3), a cell-surface protein abundantly expressed on hepatocellular carcinoma, is offering fresh evidence that carefully engineered CAR T cells can fight liver cancer — provided they are built to withstand the hostile environment of the tumour. In a commentary published in Nature Reviews Clinical Oncology, Tim F. Greten and Mitchell Ho of the National Cancer Institute examine a newly described CAR T cell product and ask a deceptively simple question: how much engineering is enough, and what must come next for the field to succeed?

The product at the centre of the discussion, known as C-CAR031, consists of autologous T cells — the patient’s own immune cells, collected and modified outside the body — that express an affinity-tuned CAR directed against glypican 3. Affinity tuning is a critical design choice: because GPC3 is expressed at lower levels on some healthy tissues, the receptor’s binding strength is calibrated so the engineered cells preferentially recognise tumour cells bearing high densities of the antigen while sparing normal tissue. This balancing act between potency and safety has long been recognised as one of the central challenges of targeting solid-tumour antigens with CAR T cells.

What distinguishes C-CAR031 from earlier GPC3-targeted constructs is its armour. The engineered T cells are modified to secrete a dominant-negative transforming growth factor beta receptor II (dnTGFβRII), a truncated receptor that sits on the cell surface and soaks up TGFβ, an immunosuppressive cytokine that is abundant in the hepatocellular carcinoma tumour microenvironment. TGFβ normally suppresses T cell activity, proliferation and effector function, effectively disarming infiltrating immune cells. By expressing a dominant-negative receptor, the CAR T cells become resistant to this suppressive signal, allowing them to retain their killing capacity inside the tumour rather than being shut down on arrival.

The clinical evaluation included 36 patients with hepatocellular carcinoma, a cancer that remains one of the leading causes of cancer-related death worldwide and for which advanced-stage options are limited. According to Greten and Ho, the initial efficacy results were promising, providing some of the clearest signals yet that armoured CAR T cells can achieve meaningful anti-tumour activity in a solid organ malignancy. The commentary’s authors suggest that the strategy of overcoming TGFβ-mediated immunosuppression represents a rational and technically feasible way to improve CAR T cell function in liver tumours, where the fibrotic, inflamed and cytokine-rich microenvironment has historically blunted adoptive cell therapies.

Yet the enthusiasm is tempered by two persistent concerns. The first is antigen loss: cancers are genetically unstable populations, and tumour cells that downregulate or lose GPC3 expression can escape recognition entirely, leaving the infused T cells blind to the disease. The second is limited progression-free survival, indicating that even when responses are achieved, they may not be durable. These twin problems — immune escape at the level of the target antigen and insufficient persistence of the therapeutic cells — echo the experience of CAR T cell therapy across solid tumours more broadly, and they frame the central question posed by the commentary’s title: how much armouring is enough?

The field has been experimenting with a growing arsenal of engineering strategies to answer that question. One alternative approach, tested in a separate clinical study, involved CAR T cells armoured to secrete interleukin-15, a cytokine that supports T cell survival and proliferation. Other preclinical work has focused on generating persistent, polyfunctional GPC3-specific CAR T cells that eliminated orthotopic hepatocellular carcinomas in mouse models, demonstrating that sustained multi-cytokine function is achievable with the right design. Each armouring strategy addresses a different vulnerability — cytokine deprivation, suppressive signalling, exhaustion — and the emerging lesson is that no single modification is likely to be sufficient on its own.

Beyond the engineered cells themselves, Greten and Ho highlight the importance of the surrounding clinical and diagnostic infrastructure. Regulatory agencies, including the US Food and Drug Administration, have issued guidance on the development of CAR T cell products, reflecting the unique manufacturing and safety considerations these living drugs entail. Meanwhile, advances in molecular imaging — such as a first-in-human case series of a glypican-3-targeted diagnostic radiopharmaceutical — may eventually allow clinicians to non-invasively assess GPC3 expression in a patient’s tumour before committing to a GPC3-directed therapy, and to monitor antigen heterogeneity across lesions and over time. Such companion diagnostics could become essential for selecting patients most likely to benefit and for detecting the antigen loss that undermines responses.

Broader momentum in the solid-tumour CAR T field lends context to the hepatocellular carcinoma results. A randomised phase 2 trial of satri-cel, a claudin-18 isoform 2-specific CAR T cell therapy for previously treated advanced gastric or gastro-oesophageal junction cancer, demonstrated that solid-tumour CAR T products can compete with standard treatment options in controlled studies. Taken together with the GPC3 data, these findings suggest that the field is approaching an inflection point, in which rational target selection, affinity tuning and microenvironmental armouring converge to produce clinically meaningful outcomes in cancers once considered off-limits to cell therapy.

What comes next, the commentary argues, is a systematic effort to determine which combinations of engineering features deliver durable benefit without unacceptable toxicity. Potential directions include multi-antigen targeting to pre-empt antigen escape, logic-gated receptors that improve tumour specificity, and rational sequencing or combination with other immunotherapies and liver cancer treatments. The authors, who declare no competing interests, emphasise that bringing CAR T cells for solid tumours into routine clinical practice will require more than promising initial efficacy: it will demand durable responses, manufacturable and reproducible products, and a deeper understanding of how engineered cells behave in the uniquely immunosuppressive landscape of the liver. C-CAR031 offers a compelling proof of principle that armouring works; the task now is to determine how much is enough, and to keep building.

Subject of Research: Armoured glypican 3-targeted CAR T cell therapy for hepatocellular carcinoma

Article Title: Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?

Article References: Greten, T. F., & Ho, M. (2026). Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01206-2

Image Credits: AI Generated

DOI: 10.1038/s41571-026-01206-2

Keywords: CAR T cells, hepatocellular carcinoma, glypican 3, TGFβ, cancer immunotherapy, solid tumours, dominant-negative TGFβ receptor II, antigen loss, tumour microenvironment, C-CAR031, adoptive cell therapy, liver cancer